Search clinical trials for: KQ-791

Total 531 results

Kaneq Bioscience Limited

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of KQ-791

Insulin Resistance | Healthy Volunteers

Canada
Kaneq Bioscience Limited

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

China
Rong Tao
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia With Failed Remission

China
Contineum Therapeutics

Completed

Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

Multiple Sclerosis

United States
Cephalon

Completed

Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe Psoriasis

Psoriasis

United States
Takeda

Completed

Single-Dose Phase 1 Study of TAK-792

Healthy Male Adults Participants

Japan
Cephalon

Completed

Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 Mutation

Leukemia, Myeloid
Alios Biopharma Inc.

Completed

A Study to Assess the PK of AL-794 Formulations in Healthy Subjects

Influenza

United Kingdom
Scorpion Therapeutics, Inc.

Recruiting

First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations

Non-Small Cell Lung Cancer | NSCLC | EGFR/HER2 Exon 20 Insertion Mutation

United States, Taiwan
Taisho Pharmaceutical Co., Ltd.

Completed

A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy

Narcolepsy

Japan, Korea, Republic of
Boehringer Ingelheim

Completed

BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis

Psoriasis
SignalChem Lifesciences Corporation

Completed

Safety Study of SLC-391 in Subjects With Solid Tumors

Solid Tumor

Canada
Amgen

Withdrawn

A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (ProxiMMity-1)

Relapsed/Refractory Multiple Myeloma
SignalChem Lifesciences Corporation
Syneos Health

Completed

Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of SLC-391 in Healthy Adult Subjects

Food-drug Interaction

Canada
BioMarin Pharmaceutical

Terminated

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

Late-onset Pompe Disease

United States, United Kingdom, Germany, France, Italy, Portugal, Belgium, Netherlands
Amgen

Completed

A Rheumatoid Arthritis (RA) Study Treating Signs and Symptoms of RA in People With RA & Receiving Methotrexate

Rheumatoid Arthritis
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.

Recruiting

An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease

Alzheimer's Disease

China
NervGen Pharma

Completed

A Phase I Safety Study of NVG-291 in Healthy Adults

Spinal Cord Injury

Australia
Cerevel Therapeutics, LLC

Completed

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

Hepatic Impairment

United States
Zoll Medical Corporation

Enrolling by invitation

Pre-hospital Ventilation Clinical Study

Heart Failure | Sepsis | Hemorrhage | Cardiac Arrest | Respiratory Distress Syndrome, Adult | Altered Mental Status

United States
Alios Biopharma Inc.

Terminated

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers

Healthy

United Kingdom
Ronald Hoffman
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Unknown

CEP-701 (Lestaurtinib) in Myelofibrosis

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States
Cephalon

Terminated

Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma

Myeloma

United States
Terns, Inc.

Not yet recruiting

CARDINAL- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase

United States
NervGen Pharma

Recruiting

NVG-291 in Spinal Cord Injury Subjects

Spinal Cord Injuries | Chronic Spinal Cord Injury | Subacute Spinal Cord Injury

United States
MiNK Therapeutics

Completed

Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2

Respiratory Distress Syndrome, Adult

United States
Amgen

Available

AMG 701 Expanded Access Program
Cerevel Therapeutics, LLC

Completed

A 2-Part Trial of CVL-751 in Subjects With Parkinson's Disease

Parkinson Disease

United States
Medivir

Completed

A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients

Osteoarthritis, Knee

Bulgaria, Georgia, Germany, Moldova, Republic of
M.D. Anderson Cancer Center

Completed

Study of ABT-751 in Patients With Refractory Hematologic Malignancies

Hematological Malignancies

United States
BioMarin Pharmaceutical

Completed

Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease

Pompe Disease

United States, United Kingdom, France, Australia, Germany
BioMarin Pharmaceutical

Terminated

Extension Study for Patients Who Have Participated in a BMN 701 Study

Pompe Disease

United States, United Kingdom, Australia, France, Germany, New Zealand
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Pharmacokinetics of HCV-796 in Healthy Japanese Men

Healthy

Japan
Wyeth is now a wholly owned subsidiary of Pfizer
ViroPharma

Completed

Study to Evaluate the Effects of Age & Gender on PK, Safety & Tolerability of HCV-796 Administered to Healthy Subjects

Healthy

United States
Abbott

Completed

A Study of ABT-751 in Patients With Colorectal Cancer

Colorectal Cancer

United States
Abbott

Completed

A Study of ABT-751 in Patients With Renal Cell Cancer

Renal Cell Cancer

Canada, United States
Ono Pharmaceutical Co. Ltd

Completed

ONO-7913 Phase I Study (ONO-7913)

Solid Tumor

Japan
Amgen

Active, not recruiting

A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications

Non-squamous Non-small Cell Lung Cancer | Epithelial Ovarian Cancer | Claudin 6-positive Advanced/Metastatic Malignant Solid Tumors

United States, Australia, Switzerland
Medivir

Completed

A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers

Healthy

United States
Millennium Pharmaceuticals, Inc.

Completed

Phase I Study of TAK-701 in Adult Patients With Advanced Nonhematological Malignancies

Advanced Solid Tumors

United States
Synvista Therapeutics, Inc

Completed

The DIAMOND Study: Distensibility Improvement And Remodeling in Diastolic Heart Failure

Pulmonary Edema | Dyspnea | Heart Failure, Congestive

United States
Boehringer Ingelheim

Terminated

Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease

Crohn Disease
TWi Biotechnology, Inc.

Completed

Prophylactic Treatment of Skin Rash Associated With EGFR Inhibitor Therapy

EGFR Inhibitor-Induced Skin Rash

Taiwan
Boehringer Ingelheim

Terminated

Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects

Healthy
Boehringer Ingelheim

Completed

Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects

Healthy
Hoya Surgical Optics, Inc.

Completed

Visual Quality Following Aspheric Intraocular Lens (IOL) Implantation - a Comparative Clinical Study (751)

Cataract | Aphakia

Australia
Boehringer Ingelheim

Completed

Excretion Balance of 14c-radiolabeled BIRB 796 BS in Normal Male Subjects

Healthy
Boehringer Ingelheim

Completed

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects

Healthy

3

Subscribe